osimertinib
astrazeneca
['adaura', 'aura ,(-laura)']
#adaura : should we continue to use adjuvant cht in stage ii-iiia? it seems yes when looking at the 5-year os rate absolute benefit of 7% in the osi arms with ady cht vs. no cht. supplementary appendix nejm
#asco23 
Medical Oncologist